C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

Review Biochemistry & Molecular Biology

Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer

Jeong Uk Lim et al.

Summary: Inflammatory cytokines are suggested to be important predictors of immunotherapy response, especially after PD-1/PD-L1 axis blockade, when their levels typically increase. Studying changes in inflammatory cytokines can help predict the response to ICI treatment and disease progression in NSCLC patients.

CYTOKINE (2021)

添加到收藏夹

Article Oncology

Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab

Shohei Fukuda et al.

Summary: The study found that the CRP flare-response group among mRCC patients was associated with significant tumor shrinkage and improved survival outcomes compared to the other two groups. Early CRP kinetics may be useful for evaluating the efficacy of nivolumab treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Laura Mezquita et al.

Summary: In patients with aNSCLC receiving ICI treatment, high dNLR at baseline (B) correlated with worse PFS/OS, while high dNLR at cycle 2 (C2) was associated with even poorer outcomes. Persistently high dNLR (B+C2) was linked to early ICI failure, suggesting immature neutrophils may play a key role in ICI resistance.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Immunology

C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma

Niklas Klumper et al.

Summary: The study validated the predictive potential of early CRP kinetics in first-line immunotherapy for mRCC. CRP responders, especially CRP flare-responders, showed significantly prolonged progression-free survival compared to non-CRP responders.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology